This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alavi K, Schwartz MZ, Palazzo JP and Prasad R, 2000, Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg. 35: 847–851.
Boushey RP, Yusta B and Drucker DJ, 1999, Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol. 277: E937–E947.
Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH and Drucker DJ, 1997, Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology. 138: 4837–4843.
Drucker DJ, 2001, Glucagon-like peptide 2. J Clin Endocrinol Metab. 86: 1759–1764.
Drucker DJ, Lovshin J, Baggio L, Nian M, Adatia F, Boushey RP, Liu Y, Saleh J, Yusta B and Scrocchi L, 2000, New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2. Ann N Y Acad Sci. 921: 226–232.
Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S and Brubaker PL, 1997, Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 15: 673–677.
Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE and Buchler MW, 2000, Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion. 62: 240–248.
Foltz M, Meyer A, Theis S, Demuth H-U and Daniel H, 2004, A rapid in vitro screening for delivery of peptidederived peptidase inhibitors as potential drug candidates via epithelial peptide transporters. J Pharmacol Exp Therap. 310: 695–702.
Geier MS, Tenikoff D, Yazbeck R, McCaughan GW, Abbott CA and Howarth GS, 2005, Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J Cell Physiol. 204: 687–692.
Hanauer SB and Baert F, 1994, Medical therapy of inflammatory bowel disease. Med Clin North Am. 78: 1413–1426.
Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB and Holst JJ, 2000a, In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 85: 2884–2888.
Hartmann B, Thulesen J, Hare KJ, Kissow, H, Orskov C, Poulsen SS and Holst JJ, 2002, Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regulatory Peptides. 105: 173–179.
Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Poulsen SS and Holst JJ, 2000b, Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology. 141: 4013–4020.
Howarth GS, Xian CJ and Read LC, 2000, Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-I for twenty weeks in a rat model of chronic inflammatory bowel disease. Growth Factors. 18: 119–133.
Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ and Mortensen PB, 2001, Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 120: 806–815.
Jeppesen PB, Hartmann B, Thulesen J, Hansen BS, Holst JJ, Poulsen SS and Mortensen PB, 2000, Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut. 47: 370–376.
Kullmann F, Messmann H, Alt M, Gross V, Bocker T, Scholmerich J and Ruschoff J, 2001, Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats. Int J Colorectal Disease. 16: 238–246.
Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ and Crivici A, 1999, Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 96: 1569–1573.
Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA and Sedergran DJ, 1993, Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 38: 1722–1734.
Rutgeerts P, Van Deventer S and Schreiber S, 2003, Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease—focus on selective adhesion molecule inhibition. Alimentary Pharmacology & Therapeutics. 17: 1435–1450.
Scott RB, Kirk D, MacNaughton WK and Meddings JB, 1998, GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 275: G911–G921.
Sigalet DL and Martin GR, 2000, Hormonal therapy for short bowel syndrome. J Pediatr Surg. 35: 360–363.
Thulesen J, Knudsen LB, Hartmann B, Hastrup S, Kissow H, Jeppesen PB, Orskov C, Holst JJ and Poulsen SS, 2002, The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regulatory Peptides. 103: 9–15.
Tsai CH, Hill M, Asa SL, Brubaker PL and Drucker DJ, 1997, Intestinal growth-promoting properties of glucagonlike peptide-2 in mice. Am J Physiol. 273: E77–E84.
Vowinkel T, Kalogeris TJ, Mori M, Krieglstein CF and Granger DN, 2004, Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Digestive Diseases & Sciences. 49: 556–564.
Xiao Q, Boushey RP, Cino M, Drucker DJ and Brubaker PL, 2000, Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol. 278: R1057–R1063.
Yamazaki, K., Yasuda, N., Inoue, T., Nagakura, T., Kira, K., Saeki, T. and Tanaka, I. (2004) The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. Eur J Pharmacol 488: 213–8.
Yusta, B., Boushey, R.P. and Drucker, D.J. (2000) The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem 275: 35345–52.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this paper
Cite this paper
Abbott, C.A., Yazbeck, R., Geier, M.S., Demuth, HU., Howarth, G.S. (2006). Dipeptidyl Peptidases and Inflammatory Bowel Disease. In: Lendeckel, U., Reinhold, D., Bank, U. (eds) Dipeptidyl Aminopeptidases. Advances in Experimental Medicine and Biology, vol 575. Springer, Boston, MA . https://doi.org/10.1007/0-387-32824-6_16
Download citation
DOI: https://doi.org/10.1007/0-387-32824-6_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-29058-4
Online ISBN: 978-0-387-32824-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)